Nature Medicine, Published online: 16 February 2026; doi:10.1038/s41591-026-04243-7 The correct diagnosis and disease prognosis of Lewy body diseases remains challenging. Two new immunoassays enable the quantification of the biomarker DOPA decarboxylase in multiple fluid samples. In the cerebrospinal fluid, elevated concentrations of DOPA decarboxylase show great potential to support the diagnosis of Lewy body disorders.
Nature Medicine, Published online: 16 February 2026;
doi:10.1038/s41591-026-04243-7
The correct diagnosis and disease prognosis of Lewy body diseases remains challenging. Two new immunoassays enable the quantification of the biomarker DOPA decarboxylase in multiple fluid samples. In the cerebrospinal fluid, elevated concentrations of DOPA decarboxylase show great potential to support the diagnosis of Lewy body disorders.
— Source: Nature Medicine (https://www.nature.com/articles/s41591-026-04243-7)